Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune cell activity while anti-VEGF augments intra-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: Wallin, Jeffrey J., Bendell, Johanna C., Funke, Roel, Sznol, Mario, Korski, Konstanty, Jones, Suzanne, Hernandez, Genevive, Mier, James, He, Xian, Hodi, F. Stephen, Denker, Mitchell, Leveque, Vincent, Cañamero, Marta, Babitski, Galina, Koeppen, Hartmut, Ziai, James, Sharma, Neeraj, Gaire, Fabien, Chen, Daniel S., Waterkamp, Daniel, Hegde, Priti S., McDermott, David F.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013615/
https://ncbi.nlm.nih.gov/pubmed/27571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12624
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares